Bank of America Securities analyst Michael Ryskin reiterated a Buy rating on Certara (CERT – Research Report) today and set a price target of $17.00.
Michael Ryskin has given his Buy rating due to a combination of factors that highlight Certara’s strategic positioning and growth potential. The company reported impressive software revenue growth, with a notable year-over-year increase, and strong software bookings, which are indicative of its expanding market presence. Certara’s focus on integrating AI-powered models into drug development processes is seen as a key driver for future growth, especially as biopharma companies seek to optimize clinical trials and accelerate drug discovery.
Ryskin also points to Certara’s positive financial performance and guidance as reasons for his optimistic outlook. The company’s revenue and bookings exceeded consensus expectations, driven by new product adoption and increased client engagement. Furthermore, Certara’s guidance for fiscal year 2025 suggests continued revenue growth and a solid adjusted EBITDA margin, reinforcing the Buy rating. The raised price objective reflects Certara’s strong position in the biosimulation and AI solutions market, balanced against industry spending challenges.
Ryskin covers the Healthcare sector, focusing on stocks such as Bruker, Danaher, and Illumina. According to TipRanks, Ryskin has an average return of 0.0% and a 46.48% success rate on recommended stocks.
In another report released today, TD Cowen also initiated coverage with a Buy rating on the stock with a $16.00 price target.